Met Life Investment Management, LLC Crispr Therapeutics Ag Transaction History
Met Life Investment Management, LLC
- $20.1 Billion
- Q3 2025
A detailed history of Met Life Investment Management, LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Met Life Investment Management, LLC holds 48,235 shares of CRSP stock, worth $2.67 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
48,235
Previous 49,339
2.24%
Holding current value
$2.67 Million
Previous $2.4 Million
30.3%
% of portfolio
0.02%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding CRSP
# of Institutions
548Shares Held
67.5MCall Options Held
3.45MPut Options Held
3.04M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl9.79MShares$541 Million4.45% of portfolio
-
Capital International Investors Los Angeles, CA5.65MShares$313 Million0.06% of portfolio
-
Orbis Allan Gray LTD Hamilton, D04.98MShares$276 Million1.8% of portfolio
-
State Street Corp Boston, MA4.01MShares$222 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.28MShares$182 Million0.13% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.32B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....